Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Indian-made Eye Surgical Dye Banned in Vietnam After Patients Go Blind; Causal Link Being Investigated

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Vietnamese health authorities are investigating whether an Indian-made dye used during eye operations might have caused 22 patients to become blind after receiving cataract surgery. Vietnam's Ministry of Health has ordered one hospital to stop using the blue dye at medical clinics following a series of incidents, according to local press reports

You may also be interested in...



Popular Demand For Healthcare, Medicines Rises As Vietnam's Economy Expands

SHANGHAI - In just one sign of surging demand for healthcare and for a wider range of medicines in Vietnam as the national economy expands, most drug makers listed on the Ho Chi Minh Stock Exchange have posted gains this year

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

Latest Headlines
See All
UsernamePublicRestriction

Register

SC075204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel